Aptose Biosciences, Inc. (APTO) Receives Average Rating of “Buy” from Analysts
Shares of Aptose Biosciences, Inc. (NASDAQ:APTO) (TSE:APS) have been given a consensus rating of “Buy” by the six analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $6.13.
APTO has been the topic of a number of analyst reports. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Monday, August 14th. HC Wainwright raised Aptose Biosciences from a “neutral” rating to a “buy” rating and increased their price target for the stock from $1.00 to $4.00 in a research report on Thursday, September 7th. Finally, ValuEngine downgraded Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
Shares of Aptose Biosciences (NASDAQ:APTO) traded down 2.21% during mid-day trading on Thursday, hitting $1.33. The stock had a trading volume of 202,205 shares. The stock has a 50 day moving average of $1.49 and a 200-day moving average of $1.29. Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $2.40. The stock’s market capitalization is $31.96 million.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.07. On average, equities research analysts predict that Aptose Biosciences will post ($1.06) earnings per share for the current year.
About Aptose Biosciences
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.